Wirkstoffe & Arzneimittelsicherheit

Gegenanzeigen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-222896 · Präparat HOS-217110

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-222897 · Präparat HOS-217110

Severe hepatic insufficiency.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-222898 · Präparat HOS-217110

Lopinavir/Ritonavir Viatris tablets contain lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A. Lopinavir/ritonavir should not be co-administered with medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life threatening events. These medicinal products include:

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Gegenanzeigen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4

HOS-222899 · Präparat HOS-217110

Medicinal product Medicinal products within Rationale class class Concomitant medicinal product levels increased Alpha1 -adrenoreceptor Alfuzosin Increased plasma concentrations of antagonist alfuzosin which may lead to severe hypotension. The concomitant administration with alfuzosin is contraindicated (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) lead (HOS-085592)

Gegenanzeigen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4–5

HOS-222902 · Präparat HOS-217110

4 Medicinal product Medicinal products within Rationale class class Antianginal Ranolazine Increased plasma concentrations of ranolazine which may increase the potential for serious and/or life-threatening reactions (see section 4.5). Antiarrhythmics Amiodarone, Increased plasma concentrations of dronedarone amiodarone and dronedarone. Thereby, increasing the risk of arrhythmias or other serious adverse reactions (see section 4.5). Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid. The concomitant administration with fusidic acid is contraindicated in dermatological infections (see section 4.5). Anticancer Neratinib Increased plasma concentrations of neratinib which may increase the potential for serious and/or life-threatening reactions (see section 4.5). Venetoclax Increased plasma concentrations of venetoclax. Increased risk of tumor lysis syndrome at the dose initiation and during the ramp-up phase (see section 4.5). Anti-gout Colchicine Increased plasma concentrations of colchicine. Potential for serious and/or life- threatening reactions in patients with renal and/or hepatic impairment (see sections 4.4 and 4.5). Antihistamines Astemizole, terfenadine Increased plasma concentrations of astemizole and terfenadine. Thereby, increasing the risk of serious arrhythmias from these agents (see section 4.5). Lurasidone Increased plasma concentrations of lurasidone which may increase the potential for serious and/or life threatening reactions (see section 4.5) Antipsychotics/ Pimozide Increased plasma concentrations of Neuroleptics pimozide. Thereby, increasing the risk of serious haematologic abnormalities, or other serious adverse effects from this agent (see section 4.5). Quetiapine Increased plasma concentrations of quetiapine which may lead to coma. The concomitant administration with quetiapine is contraindicated (see section 4.5). Ergot alkaloids Dihydroergotamine, ergonovine, Increased plasma concentrations of ergot ergotamine, methylergonovine derivatives leading to acute ergot toxicity, including vasospasm and ischaemia (see section 4.5). GI motility agent Cisapride Increased plasma concentrations of cisapride. Thereby, increasing the risk of serious arrhythmias from this agent (see section 4.5). Hepatitis C virus direct Elbasvir/grazoprevir Increased risk of alanine transaminase acting antivirals (ALT) elevations (see section 4.5). Lipid-modifying agents

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) elbasvir (HOS-108814) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) fusidic acid (HOS-086146) neratinib (HOS-086142) hepatitis C virus (HOS-108813) ergot alkaloids (HOS-108807) venetoclax (HOS-086143) lead (HOS-085592) grazoprevir (HOS-108815) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) ergotamine (HOS-086154) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) ergonovine (HOS-086153) dihydroergotamine (HOS-086152) alanine (HOS-088949)

Gegenanzeigen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5–6

HOS-222925 · Präparat HOS-217110

5  Medicinal product Medicinal products within Rationale class class HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of Inhibitors lovastatin and simvastatin; thereby, increasing the risk of myopathy including rhabdomyolysis (see section 4.5). Microsomal triglyceride Lomitapide Increased plasma concentrations of transfer protein (MTTP) lomitapide (see section 4.5). inhibitor Phosphodiesterase Avanafil Increased plasma concentrations of avanafil (PDE5) inhibitors (see sections 4.4 and 4.5) Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only. Increased plasma concentrations of sildenafil. Thereby, increasing the potential for sildenafil- associated adverse events (which include hypotension and syncope). See section 4.4 and section 4.5 for co-administration of sildenafil in patients with erectile dysfunction. Vardenafil Increased plasma concentrations of vardenafil (see sections 4.4 and 4.5) Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral midazolam and triazolam. Thereby, increasing the risk of extreme sedation and respiratory depression from these agents. For caution on parenterally administered midazolam, see section 4.5. Lopinavir/ritonavir medicinal product level decreased Herbal products St. John’s wort Herbal preparations containing St John’s wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir (see section 4.5).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-222934 · Präparat HOS-217110

Lopinavir/Ritonavir Viatris tablets contain lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A in vitro. Co-administration of lopinavir/ritonavir and medicinal products primarily metabolised by CYP3A may result in increased plasma concentrations of the other medicinal product, which could increase or prolong its therapeutic and adverse reactions. Lopinavir/ritonavir does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at clinically relevant concentrations (see section 4.3).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-222935 · Präparat HOS-217110

Lopinavir/ritonavir has been shown in vivo to induce its own metabolism and to increase the biotransformation of some medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and CYP2C19) and by glucuronidation. This may result in lowered plasma concentrations and potential decrease of efficacy of co-administered medicinal products.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-222936 · Präparat HOS-217110

Medicinal products that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse events are listed in section 4.3.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-222937 · Präparat HOS-217110

All interaction studies, when otherwise not stated, were performed using lopinavir/ritonavir capsules, which gives an approximately 20% lower exposure of lopinavir than the 200/50 mg tablets. 9 Known and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in the table below. This list is not intended to be inclusive or comprehensive. Individual SmPCs should be consulted.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-222938 · Präparat HOS-217110

Interaction table

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-222939 · Präparat HOS-217110

Interactions between lopinavir/ritonavir and co-administered medicinal products are listed in the table below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, once daily as “QD”, twice daily as “BID” and three times daily as "TID").

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-222940 · Präparat HOS-217110

Unless otherwise stated, studies detailed below have been performed with the recommended dosage of lopinavir/ritonavir (i.e. 400/100 mg twice daily).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-222941 · Präparat HOS-217110

Co-administered drug by Effects on drug levels Clinical recommendation therapeutic area Geometric Mean Change (%) in concerning co-administration with AUC, Cmax , Cmin Lopinavir/Ritonavir Viatris Mechanism of interaction Antiretroviral Agents Nucleoside/Nucleotide reverse transcriptase inhibitors (NRTIs) Lamivudine Lopinavir: ↔ No dose adjustment necessary. Abacavir, Zidovudine Abacavir, Zidovudine: The clinical significance of reduced Concentrations may be reduced due abacavir and zidovudine to increased glucuronidation by concentrations is unknown. lopinavir/ritonavir. Tenofovir disoproxil Tenofovir: No dose adjustment necessary. fumarate (DF), 300 mg QD AUC: ↑ 32% Higher tenofovir concentrations could Cmax : ↔ potentiate tenofovir associated (equivalent to 245 mg Cmin : ↑ 51% adverse events, including renal tenofovir disoproxil) disorders. Lopinavir: ↔ Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz, 600 mg QD Lopinavir: See section 4.2 for AUC: ↓ 20% Lopinavir/Ritonavir Viatris dosage Cmax : ↓ 13% recommendation or consider Cmin : ↓ 42% alternative therapy. Lopinavir/Ritonavir Viatris must not be administered once daily in combination with efavirenz. Nevirapine, 200 mg BID Lopinavir: See section 4.2 for AUC: ↓ 27% Lopinavir/Ritonavir Viatris tablets Cmax : ↓ 19% dosage recommendation or consider Cmin : ↓ 51% alternative therapy. Lopinavir/Ritonavir Viatris must not be administered once daily in combination with nevirapine. Etravirine Etravirine: No dose adjustment necessary (Lopinavir/ritonavir tablet AUC: ↓ 35% 400/100 mg BID) Cmin : ↓ 45% Cmax : ↓ 30%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) etravirine (HOS-088088) tenofovir disoproxil (HOS-108843) lamivudine (HOS-085829) fumarate (HOS-108845) zidovudine (HOS-085837) efavirenz (HOS-087947) nevirapine (HOS-088064) abacavir (HOS-088077)

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10

HOS-222949 · Präparat HOS-217110

Lopinavir: AUC: ↔ Cmin : ↓ 20% Cmax : ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11

HOS-222950 · Präparat HOS-217110

10 Co-administered drug by Effects on drug levels Clinical recommendation therapeutic area Geometric Mean Change (%) in concerning co-administration with AUC, Cmax , Cmin Lopinavir/Ritonavir Viatris Mechanism of interaction Rilpivirine Rilpivirine: Concomitant use of (Lopinavir/ritonavir AUC: ↑ 52% Lopinavir/Ritonavir Viatris with capsule 400/100 mg BID) Cmin : ↑ 74% rilpivirine causes an increase in the Cmax : ↑ 29% plasma concentrations of rilpivirine, but no dose adjustment is required. Lopinavir: AUC: ↔ Cmin : ↓ 11% Cmax : ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rilpivirine (HOS-088090)

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-222952 · Präparat HOS-217110

(inhibition of CYP3A enzymes) HIV CCR5 – antagonist Maraviroc Maraviroc: The dose of maraviroc should be AUC: ↑ 295% decreased to 150 mg twice daily Cmax : ↑ 97% during co-administration with Lopinavir/Ritonavir Viatris Due to CYP3A inhibition by 400/100 mg twice daily. lopinavir/ritonavir. Integrase inhibitor Raltegravir Raltegravir: No dose adjustment necessary AUC: ↔ Cmax : ↔ C12 : ↓ 30%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maraviroc (HOS-086186) raltegravir (HOS-086187)

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-222955 · Präparat HOS-217110

Lopinavir: ↔ Co-administration with other HIV protease inhibitors (PIs) According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended. Fosamprenavir/ ritonavir Fosamprenavir: Co-administration of increased doses (700/100 mg BID) Amprenavir concentrations are of fosamprenavir (1400 mg BID) with (Lopinavir/ritonavir significantly reduced. lopinavir/ritonavir (533/133 mg BID) 400/100 mg BID) to protease inhibitor-experienced patients resulted in a higher incidence or of gastrointestinal adverse events and elevations in triglycerides with the Fosamprenavir (1400 mg combination regimen without BID) increases in virological efficacy, when (Lopinavir/ritonavir compared with standard doses of 533/133 mg BID) fosamprenavir/ritonavir. Concomitant administration of these medicinal products is not recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) amprenavir (HOS-086183) fosamprenavir (HOS-086182)

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-222958 · Präparat HOS-217110

Lopinavir/Ritonavir Viatris must not be administered once daily in combination with amprenavir. Tipranavir/ritonavir Lopinavir: Concomitant administration of these (500/100 mg BID) AUC: ↓ 55% medicinal products is not Cmin : ↓ 70% recommended. Cmax : ↓ 47% Acid reducing agents Omeprazole (40 mg QD) Omeprazole: ↔ No dose adjustment necessary Lopinavir: ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amprenavir (HOS-086183) tipranavir (HOS-086184) omeprazole (HOS-085912)

Wechselwirkungen · Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan)

Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-222960 · Präparat HOS-217110

11 Co-administered drug by Effects on drug levels Clinical recommendation therapeutic area Geometric Mean Change (%) in concerning co-administration with AUC, Cmax , Cmin Lopinavir/Ritonavir Viatris Mechanism of interaction Ranitidine (150 mg single Ranitidine: ↔ No dose adjustment necessary dose) Alpha1 adrenoreceptor antagonist Alfuzosin Alfuzosin: Concomitant administration of Due to CYP3A inhibition by Lopinavir/Ritonavir Viatris and lopinavir/ritonavir, concentrations of alfuzosin is contra-indicated (see alfuzosin are expected to increase. section 4.3) as alfuzosin-related toxicity, including hypotension, may be increased. Analgesics Fentanyl Fentanyl: Careful monitoring of adverse effects Increased risk of side-effects (notably respiratory depression but (respiratory depression, sedation) due also sedation) is recommended when to higher plasma concentrations fentanyl is concomitantly because of CYP3A4 inhibition by administered with Lopinavir/Ritonavir lopinavir/ritonavir. Viatris.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) ranitidine (HOS-085660) fentanyl (HOS-086196)